| Filed On | Filing |
|---|---|
| 16 Jul 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 20 Jul 2017 |
8-K/A: Financial Statements and Exhibits
See accompanying notes to condensed consolidated financial statements. |
| 11 Mar 2016 |
8-K/A: Results of Operations and Financial Condition
ANNAPOLIS, MD – March 11, 2016 – PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax and owner of an affirmed judgment in its litigation with SIGA Technologies, Inc., today reported ... |
| 23 Jul 2010 |
8-K/A: Financial Statements and Exhibits
In our capacity as counsel to PharmAthene, Inc., a Delaware corporation (the “Company”), we have been asked to render this opinion in connection with a registration statement on Form S-3 (the “Registration Statement”), heretofore filed b... |
| 13 Apr 2010 |
8-K/A: Financial Statements and Exhibits
In our capacity as counsel to PharmAthene, Inc., a Delaware corporation (the “Company”), we have been asked to render this opinion in connection with a registration statement on Form S-3 (the “Registration Statement”), heretofore filed b... |
| 03 Aug 2009 |
8-K/A: Financial Statements and Exhibits
NEITHER THE ISSUANCE AND SALE OF THIS NOTE NOR ANY SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE OR PROVINCIAL S... |
| 18 Jun 2008 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the accompanying combined balance sheets of the Avecia Vaccines business of Avecia Group plc (“the Business”) as of December 31, 2007 and 2006, and the related combined statements of income, cash flows, and recognised inc... |
| 24 Sep 2007 |
8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +6 more
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT WITH RESPECT TO THE OMITTED PORTIO... |
| 24 Jan 2007 |
8-K/A: Other Events
The investor presentation attached hereto as Exhibit 99.1 is the form of slide show presentation that HAQ expects to use in presentations for certain of its stockholders in connection with HAQ’s acquisition of PharmAthene, and replaces a... |
Loading...